StreetInsider.com News Articles

Innate Pharma S.A. (IPHA) PT Raised to $9 at BTIG

Tue, 11 Aug 2026 16:02:32 -0400

BTIG analyst Jeet Mukherjee raised the price target on Innate Pharma S.A. (NASDAQ: IPHA) to $9.00 (from $8.00) while maintaining a Buy rating.

Innate Pharma S.A. (IPHA) PT Raised to $7 at H.C. Wainwright

Tue, 11 Aug 2026 06:52:59 -0400

(Updated - August 11, 2026 6:52 AM EDT)

H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Innate Pharma S.A. (NASDAQ: IPHA) to $7.00 (from $5.00) while maintaining a Buy rating.

The analyst commented: "On August 10, Innate Pharma announced a strategic partnership with Swedish Orphan Biovitrum (STO:SOBI; Buy; Kapoor) to license lacutamab, an anti-KIR3DL2 antibody in late-stage development for cutaneous T-cell lymphoma (CTCL). Recall that enrollment of TELLOMAK-3, the confirmatory Phase 3 trial, was the gating event for Innate's ability to pursue accelerated approval. The agreement is structured to enable initiation of confirmatory Phase 3 study TELLOMAK-3 and the subsequent

Innate Pharma S.A. (IPHA) PT Raised to $7 at H.C. Wainwright

Tue, 11 Aug 2026 06:52:59 -0400

(Updated - August 11, 2026 6:52 AM EDT)

H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Innate Pharma S.A. (NASDAQ: IPHA) to $7.00 (from $5.00) while maintaining a Buy rating.

Leerink Upgrades Innate Pharma S.A. (IPHA) to Outperform

Tue, 11 Aug 2026 06:11:56 -0400

Leerink analyst Daina Graybosch upgraded Innate Pharma S.A. (NASDAQ: IPHA) from Market Perform to Outperform with a price target of $4.00.

For an analyst ratings summary and ratings history on Innate Pharma S.A. click here. For more ratings news on Innate Pharma S.A. click here.

Shares of Innate Pharma S.A. closed at $2.22 yesterday.

Form 6-K Innate Pharma SA For: Aug 10

Mon, 10 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260810/26893649.html

Form 6-K Innate Pharma SA For: Aug 10

Mon, 10 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260810/26893649.html

Form 6-K Innate Pharma SA For: Aug 10

Mon, 10 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260810/26893649.html

Sobi licenses lacutamab from Innate Pharma in $75M upfront deal

Mon, 10 Aug 2026 02:33:07 -0400

Swedish Orphan Biovitrum AB (Nasdaq Stockholm: SOBI), known as Sobi, and Innate Pharma SA (Euronext Paris: IPH, NASDAQ: IPHA) announced a licensing partnership for lacutamab, an anti-KIR3DL2 antibody in development for cutaneous T-cell lymphoma (CTCL).

Under the agreement, Sobi will pay Innate Pharma $75 million upon closing. Innate is eligible to receive up to an additional $40 million in near-term development milestones tied to Sézary syndrome, and up to $465 million related to a Sobi option for full development rights and future regulatory and commercial milestones. Innate will also receive tiered double-digit royalties on net sales.

Innate will conduct the TELLOMAK-3 Phase

Sobi licenses lacutamab from Innate Pharma in $75M upfront deal

Mon, 10 Aug 2026 02:33:07 -0400

Innate will conduct the TELLOMAK-3 Phase

Sobi licenses lacutamab from Innate Pharma in $75M upfront deal

Mon, 10 Aug 2026 02:33:07 -0400

Innate will conduct the TELLOMAK-3 Phase

Sobi licenses lacutamab from Innate Pharma in $75M upfront deal

Mon, 10 Aug 2026 02:33:07 -0400

Innate will conduct the TELLOMAK-3 Phase

Sobi licenses lacutamab from Innate Pharma in $75M upfront deal

Mon, 10 Aug 2026 02:33:07 -0400

Innate will conduct the TELLOMAK-3 Phase

Sobi licenses lacutamab from Innate Pharma in $75M upfront deal

Mon, 10 Aug 2026 02:33:07 -0400

Innate will conduct the TELLOMAK-3 Phase

Sobi licenses lacutamab from Innate Pharma in $75M upfront deal

Mon, 10 Aug 2026 02:33:07 -0400

Innate will conduct the TELLOMAK-3 Phase

Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma

Mon, 10 Aug 2026 02:32:00 -0400

STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL.